High urgency

Greek national indicted for selling counterfeit and unapproved prescription drugs to internet pharmacies and undercover agents - justice.gov

Detected September 2, 2026 · in Pharmaceutical Manufacturing (FDA/DEA)

A Greek national has been indicted for selling counterfeit and unapproved prescription drugs, highlighting increased scrutiny on internet pharmacies and drug manufacturers.

Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 2, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All pharmaceutical manufacturers and internet pharmacies. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate review and compliance actions are recommended.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

Increased legal scrutiny and potential enforcement actions against those involved in selling counterfeit or unapproved drugs.

Who it affects

All pharmaceutical manufacturers and internet pharmacies.

What you must do

Review and ensure compliance with FDA regulations regarding drug approval and manufacturing practices.

Deadline

Immediate review and compliance actions are recommended.

Source: https://news.google.com/rss/articles/CBMieEFVX3lxTE5XakRDZFA2dlVDdlIzeE9XYm9YaTY4OWpPLVJsYTduS001ZHBId3E3Xy10S0Q1MjRpMzMxQzhhNHc5TDZaSGtSU0ZvSFU3cm9MUG5JcFBPYW0zemZGS1NSMmFzd0xhZDNndGlFSTlfS3FPNnRFOXd1dw?oc=5

Never miss a change like this again

Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Pharmaceutical Manufacturing (FDA/DEA)